Drug & intervention

dostarlimab

RxCUI 2539967

Clinical trials10

Recruiting0

Related conditions17

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

10 shown

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) PatientsNCT06879717 · 2025-04-22

ACTIVE_NOT_RECRUITING

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerNCT05565378 · 2022-10-14

ACTIVE_NOT_RECRUITING

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsNCT05277051 · 2022-03-22

ACTIVE_NOT_RECRUITING

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3NCT06926673 · 2021-12-23

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsNCT05060432 · 2021-09-06

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerNCT04837209 · 2021-07-21

ACTIVE_NOT_RECRUITING

Niraparib + Dostarlimab In BRCA Mutated Breast CancerNCT04584255 · 2021-01-21

ACTIVE_NOT_RECRUITING

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT04581824 · 2020-11-19

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)NCT03739710 · 2019-01-24

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsNCT03250832 · 2017-08-08

Conditions being studied

Neoplasms4 Breast Cancer2 Lung Cancer, Non-Small Cell2 Advanced Cancer1 Advanced Non Squamous NSCLC1 Deleterious PALB2 Gene Mutation1 Germline BRCA1 Gene Mutation1 Germline BRCA2 Gene Mutation1 Head and Neck Cancer1 HER2-negative Breast Cancer1 Lung Cancer1 Melanoma1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC)1 Stage I Breast Cancer1 Stage II Breast Cancer1 Stage III Breast Cancer1 Triple Negative Breast Cancer1

Research locations

BarcelonaSpain7 MálagaSpain6 MadridSpain5 BordeauxFrance4 CaenFrance4 SeoulSouth Korea4 BerlinGermany3 BostonMassachusetts, United States3 MilanItaly3 NashvilleTennessee, United States3 ParisFrance3 SevilleSpain3

Leading sponsors

GlaxoSmithKline5 Dana-Farber Cancer Institute1 iOnctura1 iTeos Belgium SA1 Massachusetts General Hospital1 Tesaro, Inc.1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.